Miglustat Bluefish (Miglustat)

Miglustat is used in substrate reduction therapy for lysosomal storage disorders.

• Niemann-Pick disease type C: improves neurological function and slows disease progression.
• Gaucher disease type 1: reduces spleen and liver volume and improves hematologic parameters.
• Lysosomal storage disorder management: provides substrate reduction to complement enzyme replacement therapy.

• Miglustat reversibly inhibits glucosylceramide synthase, the key enzyme responsible for the first step in glycosphingolipid biosynthesis. By reducing the production of glucosylceramide, it lowers the accumulation of complex glycosphingolipids in cells, thereby mitigating the pathological storage that characterises certain lysosomal storage diseases.

Miglustat may cause a range of adverse reactions.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may accompany meals.
• Abdominal pain: cramping or discomfort in the stomach area.
• Weight loss: gradual reduction in body weight during treatment.
• Tremor: mild shaking, especially of the hands.
• Headache: occasional pressure or throbbing pain.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes, requires urgent care.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Liver enzyme elevation: significant increase in ALT/AST levels, monitor liver function.
• Depression or mood changes: new or worsening psychiatric symptoms.
• Seizures: rare occurrence of convulsive episodes.

Before initiating therapy, several safety considerations are recommended.

• Dose adjustment: monitor renal function and adjust dose if impairment is present.
• Blood monitoring: check liver enzymes regularly during treatment.
• Pregnancy: use only if potential benefits outweigh risks, as safety data are limited.
• Concomitant medications: avoid strong CYP3A4 inhibitors that may increase miglustat exposure.
• Patient counseling: advise patients to report persistent gastrointestinal symptoms or neurological changes.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Miglustat can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may markedly increase miglustat plasma levels.
• Other substrate reduction agents: combined use can lead to additive toxicity.

Moderate Interactions (Monitor Closely)

• Antidiabetic drugs: miglustat may affect glucose control, requiring monitoring.
• Warfarin: monitor INR values as miglustat could influence anticoagulation.
• Antacids containing magnesium or aluminum: may reduce miglustat absorption if taken simultaneously.